Filed in March 12 (2016), the HEMERA BIOSCIENCES covers Pharmaceuticals for the treatment of. “Our aim with this novel, single-administration gene therapy is to use our development expertise and deep heritage in vision care to help improve patient outcomes by intervening early, halting the progression to blindness, and preserving more years of sight. HEMERA BIOSCIENCES is a trademark of Hemera Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, Read More > Ap. List, MD, PhD, global therapeutic area head, Cardiovascular and Metabolism, Janssen Research & Development, in the press release. CAMBRIDGE, Mass., Ap(GLOBE NEWSWIRE) Genocea Biosciences, Inc. The HEMERA BIOSCIENCES is under the trademark classification: Pharmaceutical Products The HEMERA BIOSCIENCES trademark covers Pharmaceuticals for the treatment of macular degeneration and other. This trademark was filed to USPTO on Saturday, March 12, 2016. “Geographic atrophy is a devastating form of AMD that impacts the ability to accomplish everyday tasks, such as reading, driving, cooking, or even seeing faces,” said James F. HEMERA BIOSCIENCES is a trademark and brand of Hemera Biosciences, Inc., Waltham, MA. 2, 2020 that it has acquired US-based biotechnology company Hemera Biosciences’ investigational gene therapy, HMR59, for the preservation of vision in patients with geographic atrophy, a form of age-related macular degeneration (AMD).Īccording to a Janssen press release, the gene therapy works to increase the ability of retina cells to make a soluble form of CD59, a protein that shields the retina from damage, to prevent additional damage to the retina and to preserve vision. JNJ - Free Report) pharmaceutical unit, Janssen Pharmaceuticals, Inc., announced that it has acquired rights to privately-owned biotechnology company Hemera Biosciences, LLC’s investigational gene. In geographic atrophy, which affects around 5 million people globally, an overactivity of complement destroys cells in the macula, the central part of the retina. He assumed the role of CEO in 2017 and oversaw all aspects of. An ocular gene therapy trial using AAVCAGsCD59 (Hemera Biosciences) consists of an intravitreal injection resulting in an increase in the expression of a soluble form of CD59 (sCD59), which inhibits the formation of the membrane attack complex, the terminal step of complement-mediated cell lysis. Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced on Dec. Rogers co-founded Hemera Biosciences in 2010, a clinical stage gene therapy company targeting dry age-related macular degeneration.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |